Enhancement of Ca2+ currents by GHRH and its relation to PKA and [Ca2+]i in human GH-secreting adenoma cells

Am J Physiol. 1996 Nov;271(5 Pt 1):E801-7. doi: 10.1152/ajpendo.1996.271.5.E801.

Abstract

The effects of human growth hormone-releasing hormone (hGHRH) on Ca2+ channels were examined in human growth hormone-producing adenoma cells using the perforated whole cell clamp technique. These cells exhibited T- and L-type Ca2+ channel currents, and application of 10(-8) M hGHRH increased the amplitude of both currents. Application of 10(-5) M 8-bromoadenosine 3',5'-cyclic monophosphate also increased T- and L-type currents. Additional application of 10(-8) M hGHRH did not further increase the current amplitudes. Treatment with the Rp diastereomer of adenosine 3',5'-cyclic monophosphothioate (10(-5) M) or H-89 (10(-5) M) inhibited the enhancement of Ca2+ channel currents by hGHRH, as did intracellular injection of protein kinase A (PKA) inhibitor peptide [PKI-(5-24)], indicating that hGHRH increased the amplitude of Ca2+ channel currents through the activation of the adenosine 3',5'-cyclic monophosphate (cAMP)-PKA system. When intracellular Ca2+ concentration ([Ca2+]i) was chelated to < 30 nM with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTAAM), hGHRH failed to increase the Ca2+ channel currents. In this condition, hGHRH activated nonselective cation channels, which revealed that the cAMP-PKA system operated after treatment with BAPTA-AM and that the site of low [Ca2+]i-induced inhibition of hGHRH effects on Ca2+ channels was at a step after PKA activation.

MeSH terms

  • Adenoma / physiopathology*
  • Barium / pharmacology
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels / drug effects
  • Calcium Channels / physiology*
  • Calcium Channels, L-Type
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Egtazic Acid / analogs & derivatives
  • Egtazic Acid / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Growth Hormone-Releasing Hormone / pharmacology*
  • Human Growth Hormone / metabolism*
  • Humans
  • Isoquinolines / pharmacology
  • Membrane Potentials / drug effects
  • Patch-Clamp Techniques
  • Peptide Fragments
  • Peptides / pharmacology
  • Pituitary Neoplasms / physiopathology*
  • Stereoisomerism
  • Sulfonamides*
  • Thionucleotides / pharmacology
  • Tumor Cells, Cultured
  • omega-Conotoxin GVIA

Substances

  • Calcium Channel Blockers
  • Calcium Channels
  • Calcium Channels, L-Type
  • Enzyme Inhibitors
  • Isoquinolines
  • Peptide Fragments
  • Peptides
  • Sulfonamides
  • Thionucleotides
  • protein kinase inhibitor peptide (5-24)
  • Human Growth Hormone
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • adenosine-3',5'-cyclic phosphorothioate
  • Barium
  • Egtazic Acid
  • Growth Hormone-Releasing Hormone
  • omega-Conotoxin GVIA
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Calcium